IDH2 and astrocytoma (excluding glioblastoma): In the grade III astrocytoma group, patients with I-A tumors survived much longer (66 months) than patients with IDH-mutated I-X tumors (13 months, P = 0.002) and IDH wild-type I-X tumors (22 months, P = 0.005) (Figure 4).